Long-Term Inhaled Corticosteroid Use and the Risk of Open-Angle Glaucoma in Patients with Chronic Obstructive Pulmonary Disease.
5 affiliations
- 1Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
- 2Department of Ophthalmology, Université Bourgogne Europe-CHU Dijon, Dijon, France.
- 3Clinical Investigation Center, Inserm CIC 1432, Clinical Epidemiology/Clinical Trials Unit, Université Bourgogne Europe-CHU Dijon, Dijon, France.
- 4Center for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital University Health Centre, Montreal, QC, Canada.
- 5Department of Medicine, McGill University, Montreal, QC, Canada.
Abstract
Purpose
The question of whether inhaled corticosteroids (ICS) increase the risk of open-angle glaucoma (OAG) has produced conflicting data on short-term effects, but no study has evaluated their long-term effects. We assessed whether long-term cumulative ICS use is associated with an increased risk of incident OAG among patients with chronic obstructive pulmonary disease (COPD).Patients and methods
The United Kingdom Clinical Practice Research Datalink was used to form a cohort of patients with COPD, aged 40 years or more, who initiated an inhaled maintenance treatment, between September 2013 and March 2021. Subjects were followed until the occurrence of the first OAG diagnosis. Using a nested case-control design, each OAG case was matched with up to 100 concurrently glaucoma-free controls using risk-set sampling. Conditional logistic regression was used to compute the adjusted odds ratio of incident OAG associated with cumulative ICS exposure, as an estimate of the hazard ratio (HR) and its 95% confidence interval (CI).Results
The COPD cohort included 84,564 subjects, with 732 developing OAG (incidence rate 2.64 per 1000 person-years) and 56% having used an ICS since cohort entry. The adjusted HR of OAG associated with any ICS use since cohort entry, compared with non-use, was 1.14 (95% CI, 0.94-1.38). The HR was 1.11 (95% CI, 0.83-1.48) for total cumulative dose ≥365 mg and 1.23 (95% CI, 0.90-1.68) for over 3 years since ICS initiation.Conclusion
This large cohort study did not observe a statistically significant increase in the risk of OAG with ICS use, including long-term use and higher cumulative doses, among patients with COPD.
Related
- Is It Safe to Reduce Inhaled Corticosteroid Dose in Severe Asthma Patients Receiving Biologic Therapy?
- Chronic Obstructive Pulmonary Disease in Heart Failure with Reduced Ejection Fraction: Prevalence, Prognostic, and Association of Triple Inhaled Therapy
- Changes in Symptoms and Lung Function During Three Months of Individually Tailored Inhaled Therapy in Chronic Obstructive Pulmonary Disease: A Prospective Observational Cohort Study
- Sleep Quality and Daytime Sleepiness in Patients with Chronic Obstructive Pulmonary Disease in a Tertiary Care Hospital: An Observational Study
- Development and validation of an interpretable machine learning model for early prediction of mortality in ICU patients with chronic obstructive pulmonary disease and heart failure
BibTeX
@article{ghezala2026longterm,
title = {{Long-Term Inhaled Corticosteroid Use and the Risk of Open-Angle Glaucoma in Patients with Chronic Obstructive Pulmonary Disease.}},
author = {Inès Ben Ghezala and Sophie Dell'Aniello and Pierre Ernst and Samy Suissa},
journal = {International journal of chronic obstructive pulmonary disease},
year = {2026},
month = oct,
doi = {10.2147/copd.s634969},
url = {https://europepmc.org/article/MED/42899177},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Long-Term Inhaled Corticosteroid Use and the Risk of Open-Angle Glaucoma in Patients with Chronic Obstructive Pulmonary Disease.
AU - Inès Ben Ghezala
AU - Sophie Dell'Aniello
AU - Pierre Ernst
AU - Samy Suissa
PY - 2026
DA - 2026/10/15
JO - International journal of chronic obstructive pulmonary disease
DO - 10.2147/copd.s634969
UR - https://europepmc.org/article/MED/42899177
AB - Purpose The question of whether inhaled corticosteroids (ICS) increase the risk of open-angle glaucoma (OAG) has produced conflicting data on short-term effects, but no study has evaluated their long-term effects. We assessed whether long-term cumulative ICS use is associated with an increased risk of incident OAG among patients with chronic obstructive pulmonary disease (COPD).Patients and methods The United Kingdom Clinical Practice Research Datalink was used to form a cohort of patients with COPD, aged 40 years or more, who initiated an inhaled maintenance treatment, between September 2013 and March 2021. Subjects were followed until the occurrence of the first OAG diagnosis. Using a nested case-control design, each OAG case was matched with up to 100 concurrently glaucoma-free controls using risk-set sampling. Conditional logistic regression was used to compute the adjusted odds ratio of incident OAG associated with cumulative ICS exposure, as an estimate of the hazard ratio (HR) and its 95% confidence interval (CI).Results The COPD cohort included 84,564 subjects, with 732 developing OAG (incidence rate 2.64 per 1000 person-years) and 56% having used an ICS since cohort entry. The adjusted HR of OAG associated with any ICS use since cohort entry, compared with non-use, was 1.14 (95% CI, 0.94-1.38). The HR was 1.11 (95% CI, 0.83-1.48) for total cumulative dose ≥365 mg and 1.23 (95% CI, 0.90-1.68) for over 3 years since ICS initiation.Conclusion This large cohort study did not observe a statistically significant increase in the risk of OAG with ICS use, including long-term use and higher cumulative doses, among patients with COPD.
SN - 1176-9106
SN - 1178-2005
ER -